Follow
Wei Wang
Wei Wang
Department of Oncology, University of Wisconsin-Madison
Verified email at wisc.edu
Title
Cited by
Cited by
Year
NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
W Wang, AK Erbe, JA Hank, ZS Morris, PM Sondel
Frontiers in immunology 6, 155000, 2015
6342015
Neuroblastoma patients' KIR and KIR-ligand genotypes influence clinical outcome for dinutuximab-based immunotherapy: a report from the Children's Oncology Group
AK Erbe, W Wang, L Carmichael, KM Kim, EA Mendonça, Y Song, D Hess, ...
Clinical Cancer Research 24 (1), 189-196, 2018
582018
Human NK cells maintain licensing status and are subject to killer immunoglobulin-like receptor (KIR) and KIR-ligand inhibition following ex vivo expansion
W Wang, AK Erbe, KA Alderson, E Phillips, M Gallenberger, J Gan, ...
Cancer Immunology, Immunotherapy 65, 1047-1059, 2016
432016
Stress keratin 17 enhances papillomavirus infection-induced disease by downregulating T cell recruitment
W Wang, A Uberoi, M Spurgeon, E Gronski, V Majerciak, A Lobanov, ...
PLoS Pathogens 16 (1), e1008206, 2020
332020
Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab
AK Erbe, W Wang, L Carmichael, A Hoefges, B Grzywacz, PK Reville, ...
Journal for immunotherapy of cancer 7, 1-12, 2019
252019
Association between viral loads of different oncogenic human papillomavirus types and the degree of cervical lesions in the progression of cervical Cancer
W Wang, X Zhang, M Li, C Hao, Z Zhao, H Liang
Clinica Chimica Acta 483, 249-255, 2018
212018
HLA-Bw4-I-80 isoform differentially influences clinical outcome as compared to HLA-Bw4-T-80 and HLA-A-Bw4 isoforms in rituximab or dinutuximab-based cancer immunotherapy
AK Erbe, W Wang, PK Reville, L Carmichael, KM Kim, EA Mendonca, ...
Frontiers in immunology 8, 675, 2017
212017
FCGR polymorphisms influence response to IL2 in metastatic renal cell carcinoma
AK Erbe, W Wang, J Goldberg, M Gallenberger, KM Kim, L Carmichael, ...
Clinical Cancer Research 23 (9), 2159-2168, 2017
192017
Donor selection for ex vivo-expanded natural killer cells as adoptive cancer immunotherapy
W Wang, AK Erbe, KB DeSantes, PM Sondel
Future Oncology 13 (12), 1043-1047, 2017
182017
Stress keratin 17 expression in head and neck cancer contributes to immune evasion and resistance to immune-checkpoint blockade
W Wang, T Lozar, AE Golfinos, D Lee, E Gronski, E Ward-Shaw, M Hayes, ...
Clinical Cancer Research 28 (13), 2953-2968, 2022
152022
Genotyping single nucleotide polymorphisms and copy number variability of the FCGRs expressed on NK cells
AK Erbe, W Wang, M Gallenberger, JA Hank, PM Sondel
Natural Killer Cells: Methods and Protocols, 43-56, 2016
142016
Killer immunoglobulin-like receptor (KIR) and KIR–ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2
W Wang, AK Erbe, M Gallenberger, KM Kim, L Carmichael, D Hess, ...
Cancer Immunology, Immunotherapy 65, 1523-1532, 2016
102016
Stress keratin 17 and estrogen support viral persistence and modulate the immune environment during cervicovaginal murine papillomavirus infection
W Wang, ME Spurgeon, A Pope, S McGregor, E Ward-Shaw, E Gronski, ...
Proceedings of the National Academy of Sciences 120 (12), e2214225120, 2023
82023
Abstract LB-048: Impact of KIR/KIR ligand genotype for neuroblastoma patients in a Phase 3 COG immunotherapy trial
AK Erbe, W Wang, L Carmichael, KM Kim, PK Reville, WB London, ...
Cancer Research 77 (13_Supplement), LB-048-LB-048, 2017
62017
Specific KIR and HLA genotypes affect outcomes of single-agent anti-CD20 immunotherapy of follicular lymphoma
B Grzywacz, AK Erbe, W Wang, EA Ranheim, JA Hank, KM Kim, ...
Blood 122 (21), 507, 2013
62013
Rituximab response in follicular lymphoma: contributions from KIR 2DS1 and HLA-C
AK Erbe, W Wang, B Grzywacz, EA Ranheim, JA Hank, K Kim, ...
Journal for ImmunoTherapy of Cancer 1, 1-1, 2013
52013
Stress Keratin 17 Is a Predictive Biomarker Inversely Associated with Response to Immune Check-Point Blockade in Head and Neck Squamous Cell Carcinomas and Beyond
T Lozar, I Laklouk, AE Golfinos, N Gavrielatou, J Xu, C Flynn, A Keske, ...
Cancers 15 (19), 4905, 2023
12023
Certain KIR/KIR ligand genotypes influence patient response to immunotherapy in neuroblastoma patient
PM Sondel, AK Erbe, W Wang, L Carmichael, A Hoefges, KM Kim, ...
Journal for ImmunoTherapy of Cancer 5, 2017
12017
Impact of KIR/KIR ligand genotype for neuroblastoma patients in a phase III COG immunotherapy trial.
AK Erbe, W Wang, L Carmichael, KM Kim, EA Mendonca, Y Song, D Hess, ...
Journal of Clinical Oncology 34 (15_suppl), e14014-e14014, 2016
12016
Associations of Fc gamma receptor (FcgR2a, FcgR3a and FcgR2c) genotype with outcome in metastatic renal cell carcinoma (mRCC) patients receiving high dose interleukin 2 (HD-IL2)
AK Erbe, W Wang, KM Kim, L Carmichael, MI Gallendberger, D Hess, ...
Journal for ImmunoTherapy of Cancer 3 (2), 1-2, 2015
12015
The system can't perform the operation now. Try again later.
Articles 1–20